Abiopharma

FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

BioCryst Announces Sale of European ORLADEYO®(berotralstat) Business to Neopharmed Gentili for up to $264 Million

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

Bone Biologics Files Patent Application for Bone Regeneration Technology

Eton Pharmaceuticals Announces Addition to Russell2000® and Russell 3000® Indexes

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

NUTEX HEALTH ANNOUNCES THAT IT HAS FILED A SUPPLEMENT TO ITS PROXY STATEMENT

IFF 發佈《2024 Do More Good Report》彰顯可持續發展與創新成果

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)